key: cord-0770345-x1aw6gv2
authors: Brumfiel, Caitlin M.; DiLorenzo, Ashley M.; Petronic-Rosic, Vesna M.
title: Dermatologic manifestations of COVID-19-associated multisystem inflammatory syndrome in children
date: 2020-11-01
journal: Clin Dermatol
DOI: 10.1016/j.clindermatol.2020.10.021
sha: 8f34d1f110a70681a2cd34400117a8cdc2cfa49a
doc_id: 770345
cord_uid: x1aw6gv2

Multisystem inflammatory syndrome in children (MIS-C) affects a small percentage of pediatric patients infected with COVID-19 and is characterized by fever, laboratory evidence of inflammation, multisystem involvement, and severe illness necessitating hospitalization. Skin findings are often present in these patients and while initially compared to Kawasaki disease, likely represent distinct phenomena and overall remain poorly characterized. In this retrospective review of 34 case reports and series, we identified cutaneous manifestations documented in 417 of 736 patients (57%) with MIS-C associated with COVID-19. “Rash” was the sole descriptor of skin findings in nearly half of patients. Case reports and smaller case series provided more detail, outlining a broad range of lesion morphologies (polymorphic, maculopapular, morbilliform, erythrodermic, urticarial, reticular, petechial, purpuric) in variable anatomic distribution. More thorough descriptions of dermatologic manifestations in patients with MIS-C are warranted to better characterize this syndrome, as they may lend important insight into pathogenic mechanisms of disease.

At the outset of the novel coronavirus disease 2019 (COVID-19) pandemic, it was thought that children were generally unaffected by the deadly viral infection rapidly sweeping across the globe. This was likely due to the disproportionately lower rates at which children are affected by COVID-19 compared to adults, both in terms of infection rates and symptom severity. 1,2 Despite a relatively benign clinical course for most, pediatric patients may rarely exhibit exaggerated immune responses that fall on a spectrum ranging from a mild febrile inflammatory state without multisystem involvement, to a moderate Kawasaki disease (KD)-like illness, to a severe multisystem inflammatory syndrome with shock. 3 Beginning in late April 2020, multisystem inflammatory syndrome in children (MIS-C) became an increasingly recognized hyperinflammatory phenotype in pediatric patients with evidence of COVID-19 infection. On May 14, 2020 the Centers for Disease Control (CDC) issued a national advisory to report all cases meeting criteria for MIS-C. Cases were defined as individuals aged <21 years with severe illness requiring hospitalization, minimum 24-hour history of fever (>38 degrees Celsius), laboratory evidence of inflammation, multisystem (≥2) organ involvement, and laboratory confirmed positive SARS-CoV-2 infection (via realtime reverse transcriptase polymerase chain reaction [RT-PCR] or antibody test) or epidemiologic connection to a person with COVID-19 infection (Table 1 ). 4 Following this call for reporting, 570 cases of MIS-C have been reported to the CDC as of July 29, 2020. 5 With overlapping features of KD and toxic shock syndrome, patients with MIS-C exhibit a constellation of variable mucocutaneous as well as gastrointestinal, cardiac, hematologic, and respiratory findings. [5] [6] [7] [8] Cutaneous features are present in the majority of patients with MIS-C and are currently not well characterized. Detailed descriptions of eruption morphology in these patients are limited to small case series and case reports, while larger studies typically document the presence of a "rash", but they do not elaborate further and lack precise dermatologic description. Dermatologists are instrumental in classifying this hyperinflammatory syndrome, particularly in delineating differences between the novel MIS-C associated with COVID-19 and other well-known entities such as KD, should they exist.

Individuals below the age of 18 years account for less than 8% of all COVID-19 infections in the US; 9 however, case numbers have been rising in recent months. 10 MIS-C appears to be a rare complication of COVD-19 in children with one study reporting 2 per 100,000 COVID-19 cases. 7 According to CDC data from the 570 reported MIS-C cases, median age at presentation was 8 years (range 2 weeks-20 years). 5 6, 7 Notably, however, there is likely significant patient overlap between these studies and the CDC-reported data.

In the United Kingdom, Davies et al. detailed 78 cases of pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS), which is very similar to MIS-C but with a slightly less restrictive case definition, particularly patients may exhibit single organ system dysfunction and may or may not require hospitalization. 11 Their cohort had a somewhat higher male predominance (67%) and age of presentation (median 11 years, interquartile range 8-14). 8 Regarding ethnicity, 47% of their patients were Afrocaribbean, 28% were Asian, 22% were white, and 3% were documented as other.

Underlying comorbidities were present in 22% of patients. Of note, cases of MIS-C are less prevalent, even absent, in Asia with some nations with high COVID-19 rates reporting zero cases since the start of the pandemic. [12] [13] [14] 

Skin lesions are present in anywhere from 0. 2-20% of adults with COVID-19 infection 15, 16 and are typically transient with highly variable morphology. 17 Morbilliform, urticarial, pseudochilblain, vesicular, papulosquamous, pernio-like, livedoid, and necrotic lesions have all been described in large case series and systematic reviews. 16 of these articles state "rash" as the sole descriptor of skin findings. Some smaller case series and case reports provide more detailed characterizations: polymorphic, maculopapular, morbilliform, and diffuse erythroderma were the most common morphologies noted. 3, 25, 34, [38] [39] [40] 45, 46, 48, 51 Skin lesions in single case reports were described as urticarial 34 , reticular 47 , petechial 32 , and purpuric. 46 With regard to distribution, some rashes were generalized while others were localized to the face, trunk, extremities, or acral regions. Palm and sole involvement including edema or erythema were present in some patients 30, 32, 41, 46, 47 while others had desquamation of the extremities and/or digits. 24, 30, 42, 51 Conjunctivitis and cheilitis were described in many patients. Erythema, edema, and/or induration of the extremities and/or hands and feet were also frequently reported.

The time to rash appearance in relation to fever and other symptom onset was not commonly included but ranged from day 2 to day 6 of illness [40] [41] [42] 48 , and in one case the rash appeared 12 days following positive COVID-19 test result. 40 Symptomatology was infrequently documented, but varied with skin lesions described as nonpruritic in several cases 40, 43, 48 pruritic in one 47 , and painful in another. 50 Specific dermatologic diagnoses other than KD were made in three cases of MIS-C associated with COVID-19. Target lesions consistent with erythema multiforme were described in two cases. 30 

The pathogenic mechanisms and etiology of MIS-C as it relates to COVID-19 infection are unknown. Some propose it is due to a delayed, postviral immune dysregulation as opposed to a true viral response. 52 This is supported by the fact that many children do not display typical preceding symptoms of COVID-19 infection prior to developing MIS-C. 53 Further, many patients test positive for anti-SARS-CoV-2 antibodies at the time of MIS-C diagnosis, but lack polymerase chain reaction (PCR) positivity for the virus. 32,53 Others speculate MIS-C is a result of the known ability of SARS-CoV-2 to block type I and type III interferon responses, resulting in unrestrained viral proliferation and high viral load. 54 Additionally, appropriate questions have been raised surrounding the lack of cases in Asia; is this a result of mutational differences of SARS-CoV-2 in different geographic regions or are there genetic susceptibilities which predispose individuals to develop MIS-C? Further research is necessary to address these questions.

Commonalities exist between the clinical spectrum of MIS-C and the better-known KD. KD is a medium-vessel vasculitis which occurs in young children ≤ 5 years. Clinical features of KD include prolonged fever, rash, cervical lymphadenopathy, and mucosal changes (Table 1) ; however, other organ systems (cardiovascular, hepatic, respiratory, gastrointestinal, neurologic) may be involved. 52 Like in KD, patients with MIS-C variably demonstrate a range of clinical features, including polymorphous exanthema, conjunctivitis, mucositis, and extremity changes. [6] [7] [8] Many patients with MIS-C meet criteria for complete or incomplete KD. However, gastrointestinal symptoms (abdominal pain, vomiting, diarrhea) are more predominant and cardiovascular abnormalities (myocarditis, ventricular dysfunction, coronary artery aneurysms, hypotension) are reportedly more severe in MIS-C, even in patients who lack overlapping features of KD. 6, 31, 52 Mucosal involvement is also less consistently present in MIS-C than KD. 8 Regarding laboratory evaluation, MIS-C patients demonstrate higher elevations in inflammatory markers (procalcitonin, ESR, CRP, ferritin) and relative cytopenias (leukocytopenia, thrombocytopenia), as well as elevated ventricular natriuretic peptide compared to those with KD. 31, 54 Further, patients with MIS-C are significantly older with a broader age range than the patients who traditionally develop KD. 31 An apparent predilection for Hispanic and Black populations exists in MIS-C, 6, 7, 31 whereas Asians typically have the highest rates of KD. 54 This may be a reflection of the generally higher COVID-19 infection rates in these populations in the United States 55 ; however, reports of MIS-C are nearly absent in Asia. 12, 14 While significant overlap exists among these syndromes, many of their shared features are nonspecific findings observed in numerous infectious disease processes in children. 54 Their differing epidemiologic trends and laboratory features, as well as the inconsistent overlap of their clinical signs altogether suggest these are perhaps related but distinct phenomena. Notably, however, a small subset (≤5%) of patients with KD may progress to develop "KD shock syndrome," which more closely resembles MIS-C in terms of laboratory findings and disease severity. 52 

While rare, MIS-C is a novel syndrome in pediatric patients that is increasingly recognized. Skin manifestations are present in the majority of those affected but are not well documented in the literature. More detailed descriptions of cutaneous findings by dermatologists is warranted to further characterize this syndrome, as they may yield important morphologic clues. Skin biopsies are generally not performed in children with MIS-C but could serve to better guide future understanding of pathophysiologic mechanisms of disease.

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review

Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 -COVID-NET, 14 States

Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2

Centers for Disease Control and Prevention Health Alert Network (HAN)

COVID-19-Associated Multisystem Inflammatory Syndrome in Children -United States

Multisystem Inflammatory Syndrome in U.S. Children and Adolescents

Multisystem Inflammatory Syndrome in Children in New York State

Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study

Demographic Trends of COVID-19 cases and deaths in the US reported to CDC

Guidance: Paediatric multisystem inflammatory syndrome temporally associated with COVID-19

Defining Association between COVID-19 and the Multisystem Inflammatory Syndrome in Children through the Pandemic

Pediatric Coronavirus Disease-2019-Associated Multisystem Inflammatory Syndrome

COVID-19 and Kawasaki disease in children

Clinical Characteristics of Coronavirus Disease 2019 in China

Cutaneous manifestations in COVID-19: a first perspective

Clinical and Histopathological Features and Potential Pathological Mechanisms of Skin Lesions in COVID-19: Review of the Literature

Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases

The spectrum of COVID-19-associated dermatologic manifestations: An international registry of 716 patients from 31 countries

SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases

A clinical, histopathological and laboratory study of 19 consecutive Italian paediatric patients with chilblain-like lesions: lights and shadows on the relationship with COVID-19 infection

Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic

Cardiac MRI of Children with Multisystem Inflammatory Syndrome (MIS-C) Associated with COVID-19: Case Series

Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents

Multisystem Inflammatory Syndrome in Children During the Coronavirus 2019 Pandemic: A Case Series

Severe Coronavirus Disease-2019 in Children and Young Adults in the Washington, DC, Metropolitan Region

Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children

Spectrum of Imaging Findings on Chest Radiographs, US, CT, and MRI Images in Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19

Multisystem Inflammatory Syndrome in Children Associated with Severe Acute Respiratory Syndrome Coronavirus 2 Infection (MIS-C): A Multi-institutional Study from New York City

Erythema multiforme and Kawasaki disease associated with COVID-19 infection in children

Distinct clinical and immunological features of SARS-COV-2-induced multisystem inflammatory syndrome in children

SARS-CoV-2-Induced Kawasaki-Like Hyperinflammatory Syndrome: A Novel COVID Phenotype in Children

Gastrointestinal symptoms as a major presentation component of a novel multisystem inflammatory syndrome in children (MIS-C) that is related to COVID-19: a single center experience of 44 cases

COVID-19 multisystem inflammatory syndrome in three teenagers with confirmed SARS-CoV-2 infection

Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort

Multisystem Inflammatory Syndrome in Children (MIS-C) Related to COVID-19: A New York City Experience

Hyperinflammatory shock in children during COVID-19 pandemic

Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study

Features of COVID-19 post-infectious cytokine release syndrome in children presenting to the emergency department

Novel Coronavirus Mimicking Kawasaki Disease in an Infant

Hyperinflammatory shock related to COVID-19 in a patient presenting with multisystem inflammatory syndrome in children: First case from Iran

Hyperinflammatory Syndrome in a Child With COVID-19 Treated Successfully With Intravenous Immunoglobulin and Tocilizumab

Special dermatological presentation of paediatric multisystem inflammatory syndrome related to COVID-19: erythema multiforme

COVID-19-Associated Pediatric Multisystem Inflammatory Syndrome

Pediatric Crohn Disease and Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID-19 Treated With Infliximab

Toxic shock-like syndrome and COVID-19: A case report of multisystem inflammatory syndrome in children (MIS-C)

COVID-19 and Kawasaki Disease: Novel Virus and Novel Case

Incomplete Kawasaki Disease in a Child with Covid-19

Introductory histopathological findings may shed light on COVID-19 paediatric hyperinflammatory shock syndrome

Dermatological manifestation of pediatrics multisystem inflammatory syndrome associated with COVID-19 in a 3-year-old girl

Multi-System Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Review of Clinical Presentation, Hypothetical Pathogenesis, and Proposed Management

SARS-CoV-2-Related Inflammatory Multisystem Syndrome in Children: Different or Shared Etiology and Pathophysiology as Kawasaki Disease? JAMA

Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children

The Disproportionate Impact of COVID-19 on Racial and Ethnic Minorities in the United States

Diagnostic Criteria for Multisystem Inflammatory Syndrome in Children (MIS-C) 4

Fever (documented ≥ 38.0º C ≥ 24 hours or subjective fever ≥ 24 hours)

Laboratory evidence of inflammation (elevated erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), fibrinogen, procalcitonin, D-dimer, ferritin, lactic acid dehydrogenase (LDH)

Multisystem involvement (≥2 organ systems)

Recent or current SARS-CoV-2 infection (as confirmed by RT-PCR, serology, or antigen test) or

Fever ≥ 5 days plus 4 of the 5 following: 1. Bilateral bulbar conjunctival injection 2. Oral mucositis (erythematous or fissured lips, injected pharynx, or strawberry tongue) 3. Extremity changes (erythema of palms or soles, edema of hands or feet, periungual desquamation) 4. Polymorphous rash 5. Cervical lymphadenopathy Table 1 : Diagnostic criteria for MIS-C and KD